E

EyePoint Pharmaceuticals
D

EYPT

8.93500
USD
0.60
(7.13%)
Market Closed
Volume
43,824
EPS
-2
Div Yield
-
P/E
-4
Market Cap
609,822,962
Related Instruments
    A
    ABIO
    0
    (0%)
    0.000000 USD
    A
    ALT
    -0.85500
    (-10.11%)
    7.60000 USD
    A
    AUMN
    -0.02650
    (-8.65%)
    0.28000 USD
    B
    BTAI
    0.05300
    (10.50%)
    0.55800 USD
    E
    EVOK
    0.06000
    (1.36%)
    4.46000 USD
    F
    FULC
    -0.32000
    (-9.64%)
    3.00000 USD
    H
    HOTH
    -0.04140
    (-4.81%)
    0.81860 USD
    More
News

Title: EyePoint Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.